Q-Line Biotech (NSE:QLINE) EBIT: ₹ Mil (TTM As of Mar. 2025)


NSE:QLINE Q-Line Biotech Ltd NSE:QLINE
12 GF Score
Price ₹546.50
! 2 Warning Signs
View Full Analysis

What is Q-Line Biotech EBIT?

Q-Line Biotech NSE:QLINE -5.15% 12 EBIT is ₹ Mil as of Mar. 2025. GuruFocus rates NSE:QLINE with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Q-Line Biotech's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2025 was ₹575 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Q-Line Biotech's annualized ROC % for the quarter that ended in Mar. 2025 was 11.77%. Q-Line Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 24.40%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Q-Line Biotech  (NSE:QLINE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Q-Line Biotech's annualized ROC % for the quarter that ended in Mar. 2025 is calculated as:

ROC % (Q: Mar. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2024 ) + Invested Capital (Q: Mar. 2025 ))/ count )
=696.522 * ( 1 - 44.53% )/( (2755.07 + 3811.993)/ 2 )
=386.3607534/3283.5315
=11.77 %

where

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3392.46 - 625.972 - ( 11.418 - max(0, 1402.775 - 1985.315+11.418))
=2755.07

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4554.859 - 734.904 - ( 7.962 - max(0, 1791.432 - 2646.383+7.962))
=3811.993

Note: The Operating Income data used here is one times the annual (Mar. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Q-Line Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2024  Q: Mar. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=574.638/( ( (819.394 + max(1189.292, 0)) + (1136.752 + max(1565.461, 0)) )/ 2 )
=574.638/( ( 2008.686 + 2702.213 )/ 2 )
=574.638/2355.4495
=24.40 %

where Working Capital is:

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(264.436 + 1052.41 + 657.051) - (625.972 + 0 + 158.633)
=1189.292

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(826.025 + 902.134 + 789.905) - (734.904 + 0 + 217.699)
=1565.461

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Mar. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Q-Line Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2025 )
=/15173.742
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q-Line Biotech EBIT Related Terms

Q-Line Biotech EBIT Historical Data

* Premium members only.

The historical data trend for Q-Line Biotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q-Line Biotech EBIT Chart

Q-Line Biotech Annual Data
Trend Mar23 Mar24 Mar25
EBIT
329.15 364.99 574.64

Q-Line Biotech Semi-Annual Data
Mar23 Mar24 Mar25
EBIT 329.15 364.99 574.64

NSE:QLINE vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Q-Line Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q-Line Biotech EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Q-Line Biotech's EV-to-EBIT falls into.


NSE:QLINE
12GF Score
Q-Line Biotech Ltd NSE:QLINE
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q-Line Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ₹ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹ Mil mean?
Q-Line Biotech (NSE:QLINE) has a EBIT of ₹ Mil as of Mar. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Q-Line Biotech.
Is Q-Line Biotech's EBIT too high?
Q-Line Biotech's current EBIT is ₹ Mil. Overall, Q-Line Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's EBIT compare to ABT and SYK?
Q-Line Biotech's EBIT of ₹ Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Q-Line Biotech. Q-Line Biotech's current EBIT is ₹ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current EBIT of ₹ Mil. The current EBIT is ₹ Mil. Q-Line Biotech's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current EBIT is ₹ Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q-Line Biotech Business Description

Address Kanpur Road Adjacent Transport Nagar Metro Station, 298-281, Transport Nagar, Lucknow, UP, IND, 226012
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
12GF Score

Get the complete analysis for NSE:QLINE

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹546.50
Price